The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

This review aims to provide an update of the literature on the pharmacology and toxicology
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …

ABSTRACT Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has
considerable toxicity and inter-individual variability in pharmacokinetics and …

Background: COVID-19 is a novel infectious disease caused by the severe acute respiratory
distress (SARS)-coronavirus-2 (SARS-CoV-2). Several therapeutic options are currently …

Pretransplantation adaptation of the daily dose of tacrolimus to CYP3A5 genotype is
associated with improved achievement of target trough concentration (C 0), but whether this …

CYP3A4* 22 is an allelic variant of the cytochrome P450 3A4 associated with a decreased
activity. Carriers of this polymorphism may require reduced tacrolimus (Tac) doses to reach …

Introduction In kidney transplantation, tacrolimus (TAC) is at the cornerstone of current
immunosuppressive strategies. Though because of its narrow therapeutic index, it is critical …

An external file that holds a picture, illustration, etc. Object name is BI-5-45-g003. jpg
Introduction: The advent of calcineurin inhibitors (CNIs), as the leading immunosuppressive …

Pharmacogenetics has generated many expectations for its potential to individualize therapy
proactively and improve medical care. However, despite the huge amount of reported …

Aims Inter‐individual variability in dose requirements of calcineurin inhibitors (CNI) has
been linked to genetic polymorphisms of CYP3A enzymes. CYP3A5* 3, CYP3A4* 1B and …